Seroma prevention by using Corynebacterium parvum in a rat mastectomy model.
Seroma formation is the most common complication after mastectomy and continues to be an important problem during the early postoperative period. Several surgical and medical methods have been developed to try to overcome this problem; however, so far none have been used successfully in the routine clinical practice. The aim of this study is to evaluate the effects of Corynebacterium parvum (CP) as a sclerosing agent in both prevention and treatment of seromas after mastectomy and axillary dissection in an animal model. Sixty female Sprague-Dawley rats underwent mastectomy and axillary dissection under general anaesthesia. Following surgery, the rats were treated in 1 of 3 ways. In the prevention group, 1 cm3 (0.35 mg) CP solution was injected beneath the skin flap just before closure of the incision after mastectomy. In the treatment group, animals in which a seroma was formed, the fluid was aspirated, and 1 cm3 CP solution was injected beneath the flap. In the control group, animals in which seromas formed, aspiration only was performed. The frequency of seroma formation decreased when CP solution was injected immediately after the operation (p < 0.01). In addition, seroma formation was effectively treated by CP injection when compared with the control group (p < 0.05). CP was effective as a prophylactic agent in the prevention group and as a therapeutic agent in the treatment group in this experimental model. CP injection may be useful for the management of this problem in a clinical setting.
Tekin
E
E
Department of General Surgery, Dokuz Eylul University Hospital, Izmir, Turkey.
Kocdor
M A
MA
Saydam
S
S
Bora
S
S
Harmancioglu
O
O
D000818:Animals; D001365:Axilla / Q000601:surgery; D004322:Drainage; D005122:Exudates and Transudates / Q000378:metabolism; D005260:Female; D007271:Injections, Intradermal; D008197:Lymph Node Excision / Q000009:adverse effects; D008206:Lymphatic Diseases / Q000378:metabolism / Q000517:prevention & control* / Q000628:therapy; D008408:Mastectomy / Q000009:adverse effects*; D011183:Postoperative Complications / Q000517:prevention & control* / Q000628:therapy; D011425:Propionibacterium acnes; D051381:Rats; D017207:Rats, Sprague-Dawley; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000627:therapeutic use*
D012597:Sclerosing Solutions